GeneThera Releases Results
From Initial Animal Tests of E.Coli O157:h7 Vaccine Amid
News of Increase of E.Coli Discoveries in Beef Products
Source of Article: http://www.earthtimes.org/articles/show/genethera-releases-results-from-initial,624570.shtml
|
|
Posted :
Mon, 17 Nov 2008 14:02:45 GMT
|
|
Author : GeneThera, Inc.
|
|
|
WHEAT RIDGE, Colo., Nov.
17 CO-GeneThera,Inc.
WHEAT RIDGE, Colo., Nov. 17 /PRNewswire-FirstCall/
-- GeneThera, Inc. (Pink Sheets: GTHR), today
released information about its E.Coli O157:H7 vaccine.
The vaccine consists of Live Attenuated Bacterial Vaccine to Reduce or
Inhibit Carriage and Shedding of Enterohemorrihagic
Escherichia Coli in Cattle. This vaccine was developed for use
against Shiga toxin-producing E.Coli (STEC) in cattle. This strategy is to
construct mutants that have deletion in the genes responsible for E.Coli
O157:H7 toxicity. Along with the mutation to inactivate the Shiga toxin gene,
the modified bacteria also carry a mutation that inactivates genes that
allows the growth of the E.Coli 0157:H7 in the cow intestine. These
modifications will greatly attenuate bacterial virulence.
According to Dr. Tony Milici MD,
PhD, GeneThera's Chairman and CEO, "Initial
experimental animal trials in both challenged rabbits and mice showed a
reduction of 99% E.Coli shedding in vaccinated animals when compared with
control animals." GeneThera is aggressively
pursuing a distribution partner to assist in bringing this vaccine/therapy
technology to market.
Their efforts are bolstered by the recent report from the Washington Post
dated November 10, which stated "...There were 21 beef
recalls in the United States in 2007, compared with
eight the year before. About a third of the recalls were prompted by reports
of human illness, while none of the 2006 recalls were. This year, meat
inspectors from the U.S. Department of Agriculture have continued to see more
contaminated beef samples. Through mid-October, they had recorded 50 percent
more than at the same time last year."
Officials have assumed that these numbers reflect an overall increase in the
prevalence of the E.Coli strain in cattle, but no one has been able to
explain why the dangerous bacteria have become more abundant.
Given the recent emergence of a similar product from a competitor, we feel
that now is the time to begin a full court press to bring our vaccine to the
forefront of the agricultural and food industries. We believe very strongly
that our vaccine is a far superior product to that of our competition.
To help bring awareness to GeneThera and its
efforts, we have engaged two very well known multimedia investor relations
firms, Wallst.net and StockBully.com.
Both firms are multimedia investor relation's sources that seek out promising
and mostly undiscovered companies in the market place and enable their
clients to utilize multimedia marketing to gain exposure via the information
highway.
"GeneThera is a fantastic company with a solid
business model and superior management. We are extremely pleased to have the
opportunity to assist them in their effort to increase investor awareness in
the financial market," said Adam Ben-Evi,
President of Stockbully.com.
About E.Coli O157:h7
There are a variety of Escherichia coli bacteria present in nature.
They are usually found in the intestines of healthy humans and healthy animals.
Even though these bacteria offer beneficial properties, there are those
variations, or strains that are pathogenic (have the ability to cause
disease). Escherichia coli 0157:H7 is one particular strain that is
"... an emerging cause of food borne illness ..." Symptoms such as
bloody diarrhea and abdominal cramps may be observed or no such symptoms may
appear. The elderly and children under five years old are highly susceptible
to Hemolytic Uremic Syndrome, a disease in which red blood cells are destroyed
and kidneys fail.
According to the CDC "...there may be about 70,000 infections with E.
Coli O157:H7 each year in the United States. We can
only estimate because we know that many infected people do not seek medical
care, many do not submit a stool specimen for testing, and many labs do not
test for STEC. The bacteria that make these toxins are called 'Shiga toxin
producing' E. coli, or STEC for short." Shiga toxin is one of the
most potent toxins known to man, so much so that the Centers for Disease
Control and Prevention (CDC) lists it as a potential bioterrorist agent (CDC,
n.d.).
ABOUT GENETHERA, INC.
GeneThera, Inc. is a molecular biotechnology
company located in Wheat
Ridge, Colorado.
The Company provides genetic diagnostic solutions for the veterinary and
agricultural industries with future plans to include the healthcare industry.
The Company's proprietary diagnostic solution is based on a genetic
expression assay, GES(TM), a protocol designed to function on a highly
automated Fluorogenic PCR platform. This platform
enables GeneThera to offer tests that are presently
not available from other technologies. The GES is designed for a host of
individual diseases, the current priorities being Mad Cow disease, Chronic
Wasting Disease, E. coli 0157:H7 and Johne's
disease, all diseases affecting cattle worldwide. For more information,
contact Dr. Tony Milici at
303-463-6371 or Al Goldsmith of The Goldsmith Group LLC at
303-838-4370.
This press release contains forward-looking statements, which are made
pursuant to the Safe-Harbor provisions of the Private Securities Litigation
Reform Act of 1995. Words such as "intends," "believes,"
and similar expressions reflecting something other than historical fact are
intended to identify forward-looking statements, but are not the exclusive
means of identifying such statements. These forward-looking statements
involve a number of risks and uncertainties, including the timely development
and market acceptance of products and technologies, the ability to secure additional
sources of finance, the ability to reduce operating expenses, and other
factors described in the Company's filings with the Securities and Exchange
Commission. The actual results that the Company achieves may differ
materially from any forward-looking statement due to such risks and
uncertainties. The Company undertakes no obligation to revise or update any
forward-looking statements in order to reflect events or circumstances that
may arise after the date of this release.
Dr. Tony Milici 303-463-6371
Goldsmith Group 303-838-4370
JR Dopkin & Associates
516-884-3200
|
